Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.57% | -33.73% | 8.53% | -- | -- |
| Total Depreciation and Amortization | -3.11% | -32.32% | -12.33% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -185.82% | -49.26% | -138.74% | -- | -- |
| Change in Net Operating Assets | -194.74% | -180.45% | -80.80% | -- | -- |
| Cash from Operations | -130.99% | -116.86% | -85.85% | -- | -- |
| Capital Expenditure | 100.00% | 145.73% | -39.42% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 135.86% | 160.06% | 10.58% | -- | -- |
| Total Debt Issued | 3,050.31% | 443.16% | -- | -- | -- |
| Total Debt Repaid | -118.40% | -118.40% | -118.40% | -- | -- |
| Issuance of Common Stock | 158.32% | 72.14% | 129.14% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 201.44% | 230.84% | 232.20% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,039.86% | 4,617.87% | 1,361.81% | -- | -- |